Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries

TOKYO, Aug 31, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in five ASEAN (Association of Southeast Asian Nations) member states:... » read more

Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand
Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand

TOKYO, Jul 19, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand. This is the first launch of Goofice in the Asian region excluding Japan. Goofice, which Eisai’s subsidiary for... » read more